Executive CHAIRMAN and President
Mr. Weisman is an accomplished entrepreneur in the life sciences industry. Mr. Weisman was previously the CEO of Seventh Sense Biosystems, a health technology company developing a breakthrough painless diagnostic blood collection platform. Prior to joining Seventh Sense, he was the founder, chairman, and CEO of EKR Therapeutics, a specialty pharmaceutical company focused on the hospital critical care market. He also co-founded ESP Pharma, where he served as a director as well as the company’s president and chief operating officer until its sale to PDL Biopharma in 2005.
Mr. Weisman began his career in sales and marketing at Merck & Co., later moving to Parke-Davis where he launched that company’s diabetes franchise in 1997. He graduated with a BA in chemistry from Rutgers University
Chief Financial Officer
Milan Kofol is an experienced financial executive in the medical device and pharmaceutical industries. Mr. Kofol served as Vice President Treasurer and Investor Relations at Boston Scientific Corporation. Prior financial experience includes audit, domestic and international controllership and treasury positions at Wyeth Pharmaceuticals. Mr. Kofol received his BA degree from Presbyterian College and MBA from Wharton School. He also holds CPA certification.
Chief Science Officer
Dr. Hoang (PhD) brings strong interdisciplinary scientific training to Sofregen. As a co-founder of Sofregen, Dr. Hoang leverages her 10+ years of biomedical research experience with her strategic vision to bring silk-based products to market. She has built a strong R&D team and developed a robust regulatory strategy for the company to bring these products to market. Dr. Hoang has published her research in high impact peer-reviewed journals. She is also an active member of the New England Women in Science Executives Club and on the Mount Holyoke College Career Development Leadership Board. She earned her doctorate degree in interdisciplinary material science engineering from Vanderbilt University as a National Science Foundation (IGERT) graduate fellow. She completed her post-doctoral training in biomedical engineering at Harvard Medical School/Massachusetts General Hospital as an Executive Committee on Research (ECOR) fellow.